Bullfrog AI Holdings Announced That The United States Patent And Trademark Office Will, On August 1, 2023, Issue U.S. Patent No. 11,712,435 Protecting The Company's Novel Prodrugs Derived From Mebendazole And Their Use In Treating Cancers, Other Diseases
Portfolio Pulse from Benzinga Newsdesk
Bullfrog AI Holdings has announced that the United States Patent and Trademark Office will issue U.S. Patent No. 11,712,435 on August 1, 2023. The patent protects the company's novel prodrugs derived from Mebendazole and their use in treating cancers and other diseases.
July 25, 2023 | 11:56 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The issuance of the patent to Bullfrog AI Holdings for its novel prodrugs could potentially strengthen the company's position in the market and provide a competitive edge.
The patent protection for Bullfrog AI Holdings' novel prodrugs derived from Mebendazole could potentially provide the company with a unique selling proposition, giving it a competitive advantage in the market. This could lead to increased investor confidence and potentially a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100